Devonian Health Group Inc. reports developments as a clinical-stage biopharmaceutical company focused on therapies for fibro-inflammatory diseases. Company news centers on Thykamine™, including preclinical data in MASH and pulmonary fibrosis models, anti-inflammatory and anti-fibrotic research, intellectual-property filings, manufacturing controls and its radiodermatitis prevention program.
Recurring updates also cover Devonian's cosmeceutical activities, its Quebec extraction facility and Altius Healthcare Group LP, a commercialization subsidiary that sells licensed prescription pharmaceutical products in Canada. Corporate news includes financial results, board and management changes, shareholder meeting outcomes, stock-option grants and capital-structure actions such as its common-share consolidation.
Devonian Health Group Inc. (TSXv: GSD; OTCQB: DVHGF) held its Annual General and Special Meeting on March 17, 2023, with 42.54% of shares represented. Six board members were elected, including Ashish Chabria and Luc Grégoire. The reappointment of PricewaterhouseCoopers as auditors received unanimous approval. Additionally, both the Corporate Stock Option Plan and Restricted Share Unit Plan were ratified by 99.72% of shareholders. Devonian focuses on developing botanical pharmaceuticals and cosmeceuticals, targeting inflammatory-autoimmune diseases and leveraging FDA regulatory guidelines for more efficient drug development.
Devonian Health Group Inc. (DVHGF), a clinical stage botanical pharmaceutical company, announced its Hybrid Annual General and Special Meeting to be held on March 17, 2023, at 14:00 Eastern Time. The meeting will take place both in-person at Hotel Le Bonne Entente in Québec and virtually via a web-based platform. Registered shareholders can access the webcast starting at 13:45 PM. Devonian specializes in developing prescription botanical drugs for inflammatory-autoimmune diseases and also creates cosmeceutical products. The firm is backed by over 15 years of research and a state-of-the-art extraction facility, with a focus on regulatory efficiencies for botanical drug development.
Devonian Health Group Inc. (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical company, announced that its CEO, Pierre Montanaro, will present at the BIO CEO & Investor Conference in New York City from February 6-9, 2023. He is scheduled to provide an overview of Thykamine™, Devonian's lead product, during the presentation on February 7 at 4:30 PM ET. The conference, now in its 25th year, connects biotech leaders and investors to discuss advancements and market outlooks in the industry. Devonian focuses on developing prescription botanical drugs for inflammatory-autoimmune diseases and high-value cosmeceuticals, backed by over 15 years of research.
Devonian Health Group Inc. (TSXv: GSD; OTCQB: DVHGF) has announced executive changes to enhance its management as it embarks on a new phase of development at its subsidiary, Altius Healthcare. Érick Shields has been appointed as Chief Commercial Officer, succeeding Sybil Dahan, who will remain as chair of Devonian's Board of Directors. The company granted stock options totaling 1,150,000, including 100,000 to directors and 50,000 to an employee, with prices ranging from $0.34 to $0.50, exercisable for ten years.
Devonian Health Group Inc. (DVHGF), a botanical pharmaceutical company, announced participation in three Renmark Financial Communications Inc. Virtual Non-Deal Roadshows. The events will take place in New York on October 25, Boston on November 10, and Toronto on December 8, 2022, featuring CEO Pierre Montanaro and CSO Dr. André P. Boulet. They will discuss the latest corporate updates followed by a Q&A session. Interested investors can register for the events online to learn more about Devonian's innovative portfolio, including its flagship product, Thykamine™.
Devonian Health Group Inc. (TSXV: GSD; OTCQB: DVHGF) announced its participation in the 6th Annual Dermatology Drug Development Summit from November 1-3, 2022 in location value="LU/us.ma.boston"Boston, MA. The company will present results from Thykamine™’s Phase 2 clinical trial focused on atopic dermatitis and inflammatory skin diseases. Thykamine™, derived from Devonian’s SUPREX™ platform, demonstrates potential in treating inflammation and oxidative stress conditions like ulcerative colitis and atopic dermatitis, backed by multiple clinical studies.
Devonian Health Group announced positive results from the Phase 2 trial of Thykamine™ for treating mild-to-moderate Atopic Dermatitis (AD), published in the Journal of Drugs in Dermatology. In this multicenter trial involving 162 patients, 30.8% achieved clear/almost clear skin compared to 6.7% in the placebo group. Statistically significant improvements were also observed in pruritus, Body Surface Area, and Patient-Oriented Eczema Measure scores. Thykamine™ demonstrated rapid action and was well tolerated, positioning it as a promising treatment in a market expected to exceed $21.8 billion by 2027.
Devonian Health Group Inc. (OTCQB: DVHGF) announced the issuance of 87,840 units at $0.40 each to settle interest owed to debenture holders from a private placement dated August 31, 2018, totaling $35,136. Each unit comprises a subordinate voting share and a warrant priced at $0.52 for a four-year period. The issuance awaits approval from the TSX Venture Exchange and is subject to a four-month hold period. Devonian specializes in developing botanical pharmaceuticals for autoimmune diseases and has a state-of-the-art extraction facility in Quebec.
Devonian Health Group Inc. (TSXv: GSD; OTCQB: DVHGF) announces significant executive changes as it enters a growth phase. Pierre Montanaro is appointed as President & CEO, while Sybil Dahan becomes Chairman of the Board. This restructuring also impacts Altius Healthcare Inc., where Montanaro will serve as CEO. The company granted stock options at $0.50 each, totaling 500,000 for Montanaro. Additionally, Devonian settled interest on a convertible debenture to Aspri Pharma, issuing units worth $49,589, while repaying a $1 million principal. Devonian focuses on botanical pharmaceuticals and cosmeceuticals.
Devonian Health Group Inc. announced the acceptance for publication of positive Phase 2 trial results for Thykamine™ in treating mild-to-moderate Atopic Dermatitis in the Journal of Drugs in Dermatology. Conducted in 162 patients, the trial demonstrated significant efficacy, particularly with the 0.10% cream formulation, which showed statistical significance across primary and secondary endpoints. This publication highlights the potential of Thykamine™ as an effective botanical treatment amidst rising global demand for Atopic Dermatitis therapies, predicted to surpass $21.8 billion by 2027.